Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
True North: Ozanimod in Ulcerative Colitis
NCT02435992Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of ozanimod in ulcerative colitis (UC), sponsored by Celgene Corporation. Started Jun 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02435992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435992.